TP53 mutations and SNPs as prognostic and predictive factors in patients with breast cancer (Review)

Huszno,Joanna; Grzybowska,Ewa

doi:10.3892/ol.2018.8627

TP53 mutations and SNPs as prognostic and predictive factors in patients with breast cancer (Review)

Authors:
- Joanna Huszno
- Ewa Grzybowska
View Affiliations

Affiliations: Outpatient Clinic, Maria Skłodowska‑Curie Memorial Cancer Center and Institute of Oncology, 44‑101 Gliwice, Poland, Center for Translational Research and Molecular Biology of Cancer, Maria Skłodowska‑Curie Memorial Cancer Center and Institute of Oncology, 44‑101 Gliwice, Poland
Published online on: May 3, 2018 https://doi.org/10.3892/ol.2018.8627
Pages: 34-40

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumor protein 53 (TP53) is a tumor suppressor gene that encodes tumor protein p53. Tumor protein p53 regulates the expression of target genes in response to cellular stress. Additionally, p53 participates in the regulation of cell cycle checkpoints, DNA repair and apoptosis. Mutations in the TP53 gene are associated with numerous types of human cancer, including breast cancer, sarcomas, brain tumors and adrenal cortical carcinomas. In breast cancer, TP53 mutations are a negative prognostic factor. Tumors with TP53 mutations are more likely to be aggressive (triple‑negative or human epidermal growth factor receptor 2‑positive breast cancer), and resistant to chemotherapy and radiotherapy. In addition to a well‑known TP53 mutation, a number of single nucleotide polymorphisms have been systematically identified and evaluated in human populations. In the present article, the role of TP53 mutations and polymorphisms in clinical practice and breast cancer treatment has been described. Additionally, the existing data on TP53 polymorphisms in breast cancer as prognostic and predictive factors have been summarized. A literature search of these topics was performed through PubMed and abstracts of the main cancer congresses in recent years.

View Figures

View References

1	Tokino T and Nakamura Y: The role of p53-target genes in human cancer. Crit Rev Oncol Hematol. 33:1–6. 2000. View Article : Google Scholar : PubMed/NCBI
2	Kratz CP, Achatz MI, Brugières L, Frebourg T, Garber JE, Greer MC, Hansford JR, Janeway KA, Kohlmann WK, McGee R, et al: Cancer screening recommendations for individuals with Li-Fraumeni syndrome. Clin Cancer Res. 23:e38–e45. 2017. View Article : Google Scholar : PubMed/NCBI
3	Wilson JR, Bateman AC, Hanson H, An Q, Evans G, Rahman N, Jones JL and Eccles DM: A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations. J Med Genet. 47:771–774. 2010. View Article : Google Scholar : PubMed/NCBI
4	Melhem-Bertrandt A, Bojadzieva J, Ready KJ, Obeid E, Liu DD, Gutierrez-Barrera AM, Litton JK, Olopade OI, Hortobagyi GN, Strong LC and Arun BK: Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer. 118:908–913. 2012. View Article : Google Scholar : PubMed/NCBI
5	Lalloo F, Varley J, Moran A, Ellis D, O'dair L, Pharoah P, Antoniou A, Hartley R, Shenton A, Seal S, et al: BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives 1. Eur J Cancer. 42:1143–1150. 2006. View Article : Google Scholar : PubMed/NCBI
6	Olivier M, Langerød A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bièche I, et al: The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res. 12:1157–1167. 2006. View Article : Google Scholar : PubMed/NCBI
7	Varna M, Bousquet G, Plassa LF, Bertheau P and Janin A: TP53 status and response to treatment in breast cancers. J Biomed Biotechnol. 2011:2845842011. View Article : Google Scholar : PubMed/NCBI
8	Wang Y, Helland Å, Holm R, Skomedal H, Abeler VM, Danielsen HE, Tropé CG, Børresen-Dale AL and Kristiansen GB: TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival. Br J Cancer. 90:678–685. 2004. View Article : Google Scholar : PubMed/NCBI
9	Langerød A, Zhao H, Borgan Ø, Nesland JM, Bukholm IR, Ikdahl T, Kåresen R, Børresen-Dale AL and Jeffrey SS: TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res. 9:R302007. View Article : Google Scholar : PubMed/NCBI
10	Chae BJ, Bae JS, Lee A, Park WC, Seo YJ, Song BJ, Kim JS and Jung SS: p53 as a specific prognostic factor in triple-negative breast cancer. Jap J Clin Oncol. 39:217–224. 2009. View Article : Google Scholar
11	Weisman PS, Ng CK, Brogi E, Eisenberg RE, Won HH, Piscuoglio S, De Filippo MR, Ioris R, Akram M, Norton L, et al: Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology. Mod Pathol. 29:476–488. 2016. View Article : Google Scholar : PubMed/NCBI
12	Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Ouesnel B, Deryite I, Morel P and Fenaux P: 53 Mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood. 84:3148–3157. 1994.PubMed/NCBI
13	Børresen-Dale AL: TP53 and breast cancer. Hum Mutat. 21:292–300. 2003. View Article : Google Scholar : PubMed/NCBI
14	Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R and Ishioka C: Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA. 100:8424–8429. 2003. View Article : Google Scholar : PubMed/NCBI
15	National Cancer Institute (NCI): NCI dictionary of cancer terms. https://www.cancer.gov/publications/dictionaries/cancer-terms
16	Komarova EA, Chumakov PM and Gudcov AV: Molecular genetics of cancer. TP53 in cancer origin and treatment. Edited by Cowell JK. 9:195–221. 2009.
17	Hasty P and Christy BA: p53 as an intervention target for cancer and aging. Pathobiol Aging Age Relat Dis. 3:227022013. View Article : Google Scholar
18	National Center for Biotechnology Information: The p53 tumor suppressor proteinGenes and Disease [Internet]. National Center for Biotechnology Information; Bethesda, MD, USA:
19	Sionov RV, Hayon IL and Haupt Y: The regulation of p53 growth suppression. Madame Curie Bioscience Database [Internet]Landes Bioscience. Austin, TX: 2000–2013
20	Shi D and Gu W: Dual roles of MDM2 in the regulation of p53. Ubiquitination dependent and ubiquitination independent mechanisms of MDM2 repression of p53 activity. Genes Cancer. 3:240–248. 2012. View Article : Google Scholar : PubMed/NCBI
21	Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, Anderson CW and Appella E: DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12:2831–2841. 1998. View Article : Google Scholar : PubMed/NCBI
22	Hill KA and Sommer SS: p53 as a mutagen test in breast cancer. Environ Mol Mutagen. 39:216–227. 2002. View Article : Google Scholar : PubMed/NCBI
23	Pharoah PD, Day NE and Caldas C: Somatic mutations in the p53 gene and prognosis in breast cancer: A meta-analysis. Br J Cancer. 80:1968–1973. 1999. View Article : Google Scholar : PubMed/NCBI
24	Hainaut P and Hollstein M: p53 and human cancer: The first ten thousand mutations. Adv Cancer Res. 77:81–137. 2000. View Article : Google Scholar : PubMed/NCBI
25	Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, et al: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 250:1233–1238. 1990. View Article : Google Scholar : PubMed/NCBI
26	Achatz MI, Olivier M, Le Calvez F, Martel-Planche G, Lopes A, Rossi BM, Ashton-Prolla P, Giugliani R, Palmero EI, Vargas FR, et al: The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Lett. 245:96–102. 2007. View Article : Google Scholar : PubMed/NCBI
27	Campomenosi P, Monti P, Aprile A, Abbondandolo A, Frebourg T, Gold B, Crook T, Inga A, Resnick MA, Iggo R and Fronza G: p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements. Oncogene. 20:3573–3579. 2001. View Article : Google Scholar : PubMed/NCBI
28	Gasco M, Yulug IG and Crook T: TP53 mutations in familial breast cancer: Functional aspects. Hum Mutat. 21:301–306. 2003. View Article : Google Scholar : PubMed/NCBI
29	Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC and Hainaut P: The IARC TP53 database: New online mutation analysis and recommendations to users. Hum Mutat. 19:607–614. 2002. View Article : Google Scholar : PubMed/NCBI
30	Li FP and Fraumeni JF Jr: Soft-tissue sarcomas, breast cancer, and other neoplasms: A familial syndrome? Ann Intern Med. 71:747–752. 1969. View Article : Google Scholar : PubMed/NCBI
31	Li FP, Fraumeni JF Jr, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA and Miller RW: A cancer family syndrome in twenty-four kindreds. Cancer Res. 48:5358–5362. 1998.
32	Birch JM, Heighway J, Teare MD, Kelsey AM, Hartley AL, Tricker KJ, Crowther D, Lane DP and Santibáñez-Koref MF: Linkage studies in a Li-Fraumeni family with increased expression of p53 protein but no germline mutation in p53. Br J Cancer. 70:1176–1181. 1994. View Article : Google Scholar : PubMed/NCBI
33	Brugières L, Gardes M, Moutou C, Chompret A, Meresse V, Matin A, Poisson N, Flamand F, Bonaïti-Pellié C, Lemerie J, et al: Screening for germ line p53 mutations in children with malignant tumors and a family history of cancer. Cancer Res. 53:452–455. 1993.PubMed/NCBI
34	Varley JM, Evans DG and Birch JM: Li-Fraumeni syndrome-a molecular and clinical review. Br J Cancer. 76:1–14. 1997. View Article : Google Scholar : PubMed/NCBI
35	Chompret A, Abel A, Stoppa-Lyonnet D, Brugiéres L, Pagés S, Feunteun J and Bonaïti-Pellié C: Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet. 38:43–47. 2001. View Article : Google Scholar : PubMed/NCBI
36	Hu H, Liu J, Liao X, Zhang S, Li H, Lu R, Li X, Lin W, Liu M, Xia Z, et al: Genetic and functional analysis of a Li Fraumeni syndrome family in China. Sci Rep. 6:202212016. View Article : Google Scholar : PubMed/NCBI
37	Olivier M, Hollstein M and Hainaut P: TP53 mutations in human cancers: Origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2:a0010082010. View Article : Google Scholar : PubMed/NCBI
38	Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P and Eeles RA: Li-Fraumeni and related syndromes: Correlation between tumor type, family structure, and TP53 genotype. Cancer Res. 63:6643–6650. 2003.PubMed/NCBI
39	Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P and Olivier M: Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database. Hum Mutat. 28:622–629. 2007. View Article : Google Scholar : PubMed/NCBI
40	Leroy B, Fournier JL, Ishioka C, Monti P, Inga A, Fronza G and Soussi T: The TP53 website: An integrative resource center for the TP53 mutation database and TP53 mutant analysis. Nucleic Acids Res. 41:(Database Issue). D962–D969. 2013. View Article : Google Scholar : PubMed/NCBI
41	Assumpção JG, Seidinger AL, Mastellato MJ, Ribeiro RC, Zambetti GP, Ganti R, Srivastava K, Shurtleff S, Pei D, Zeferino LC, et al: Association of the germline TP53 R337H mutation with breast cancer in southern Brazil. BMC Cancer. 8:3572008. View Article : Google Scholar : PubMed/NCBI
42	Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P and Olivier M: TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes. Oncogene. 26:2157–2165. 2007. View Article : Google Scholar : PubMed/NCBI
43	Brachmann RK, Vidal M and Boeke JD: Dominant-negative p53 mutations selected in yeast hit cancer hot spots. Proc Natl Acad Sci USA. 93:4091–4095. 1996. View Article : Google Scholar : PubMed/NCBI
44	Soussi T: The p53 tumor suppressor gene: From molecular biology to clinical investigation. Ann N Y Acad Sci. 910:121–139. 2000. View Article : Google Scholar : PubMed/NCBI
45	Bull SB, Ozcelik H, Pinnaduwage D, Blackstein ME, Sutherland DAJ, Pritchard KI, Tzontcheva AT, Sidlofsky S, Hanna WM, Qizilbash AH, et al: The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer. J Clin Oncol. 22:86–96. 2004. View Article : Google Scholar : PubMed/NCBI
46	Overgaard J, Yilmaz M, Guldberg P, Hansen LL and Alsner J: TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer. Acta Oncol. 39:327–333. 2000. View Article : Google Scholar : PubMed/NCBI
47	Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET and Bergh J: An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA. 102:13550–13555. 2005. View Article : Google Scholar : PubMed/NCBI
48	Andersson J, Larsson L, Klaar S, Holmberg L, Nilsson J, Inganäs M, Carlsson G, Ohd J, Rudenstam CM, Gustavsson B and Bergh J: Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF. Ann Oncol. 16:743–748. 2005. View Article : Google Scholar : PubMed/NCBI
49	Knoop AS, Bentzen SM, Nielsen MM, Rasmussen BB and Rose C: Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol. 19:3376–3384. 2001. View Article : Google Scholar : PubMed/NCBI
50	Berry DA, Muss HB, Thor AD, Dressler L, Liu ET, Broadwater G, Budman DR, Henderson C, Barcos M, Hayes D and Norton L: HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol. 18:3471–3479. 2000. View Article : Google Scholar : PubMed/NCBI
51	Bergh J, Norberg T, Sjögren S, Lindgren A and Holmberg L: Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med. 1:1029–1034. 1995. View Article : Google Scholar : PubMed/NCBI
52	Berns EM, Foekens JA, Vossen R, Look MP, Devilee P, Henzen-Logmans SC, van Staveren IL, van Putten WL, Inganäs M, Meijer-van Gelder ME, et al: Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res. 60:2155–2162. 2000.PubMed/NCBI
53	Powell BL, Bydder S, Grieu F, Gnanasampanthan G, Elsaleh H, Seshadri R, Berns EMJJ and Iacopetta B: Prognostic value of TP53 gene mutation in adjuvant treated breast cancer patients. Breast Cancer Res Treat. 69:65–68. 2001. View Article : Google Scholar : PubMed/NCBI
54	Clahsen PC, van de Velde CJ, Duval C, Pallud C, Mandarad AM, Delobelle-Deroide A, van den Broek L, Sahmoud TM and van den Vijver: p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J Clin Oncol. 16:470–479. 1998. View Article : Google Scholar : PubMed/NCBI
55	Cuny M, Kramar A, Courjal F, Johannsdottir V, Iacopetta B, Fontaine H, Grenier J, Culine S and Theillet C: Relating genotype and phenotype in breast cancer: An analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. Cancer Res. 60:1077–1083. 2000.PubMed/NCBI
56	Thorlacius S, Börresen AL and Eyfjörd JE: Somatic p53 mutations in human breast carcinomas in an Icelandic population: A prognostic factor. Cancer Res. 53:1637–1641. 1993.PubMed/NCBI
57	Bueno Martinez A, Molina MA, Fielding A, Bertran-Alamillo J, Dougherty BA, Lai Z, Hodgson D, de las Casas Mayo C, Rowe P, Gil M, et al: LBA42-Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer. ESMO. 2017.
58	Dahabreh IJ, Schmid CH, Lau J, Varvarigou V, Murray S and Trikalinos TA: Genotype misclassification in genetic association studies of the rs1042522 TP53 (Arg72Pro) polymorphism: A systematic review of studies of breast, lung, colorectal, ovarian, and endometrial cancer. Am J Epidemiol. 177:1317–1325. 2013. View Article : Google Scholar : PubMed/NCBI
59	Beckman G, Birgander R, Själander A, Saha N, Holmberg PA, Kivelä A and Beckman L: Is p53 polymorphism maintained by natural selection? Hum Hered. 44:266–270. 1994. View Article : Google Scholar : PubMed/NCBI
60	Langerod A, Burdette L, Yeager M, Presswalla S, et al: Pattern of genetic variation in the tp53 locus indicates linkage disequilibrium extends across the flanking genes, ATP1B2 and WDR79. Hum Mutat (in press). 2006.
61	Pim D and Banks L: p53 Polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer. 108:196–199. 2004. View Article : Google Scholar : PubMed/NCBI
62	Siddique M and Sabapathy K: Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene. 25:3489–3500. 2006. View Article : Google Scholar : PubMed/NCBI
63	Dumont P, Leu JI, Della Pietra AC III, George DL and Murphy M: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 33:357–365. 2003. View Article : Google Scholar : PubMed/NCBI
64	Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, et al: A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 119:591–602. 2004. View Article : Google Scholar : PubMed/NCBI
65	Harris SL, Gil G, Hu W, Robins H, Bond E, Hirshfield K, Feng Z, Yu X, Teresky AK, Bond G and Levine AJ: Single-nucleotide polymorphisms in the p53 pathway. Cold Spring Harb Symp Quant Biol. 70:111–119. 2005. View Article : Google Scholar : PubMed/NCBI
66	Toyama T, Zhang Z, Nishio M, Hamaguchi M, Kondo N, Iwase H, Iwata H, Takahashi S, Yamashita H and Fujii Y: Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res. 9:R342007. View Article : Google Scholar : PubMed/NCBI
67	Paulin FE, O'Neill M, McGregor G, Cassidy A, Ashfield A, Ali CW, Munro AJ, Baker L, Purdie CA, Lane DP and Thompson AM: MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism. BMC Cancer. 8:2812008. View Article : Google Scholar : PubMed/NCBI
68	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®): Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version I. simpleNCCN.orgFort Washington, DC: 2015
69	Hu Z, Li X, Qu X, He Y, Ring BZ, Song E and Su L: Intron 3 16 bp duplication polymorphism of TP53 contributes to cancer susceptibility: A meta-analysis. Carcinogenesis. 31:643–647. 2010. View Article : Google Scholar : PubMed/NCBI
70	Bellini I, Pitto L, Marini MG, Porcu L, Moi P, Garritano S, Boldrini L, Rainaldi G, Fontanini G, Chiarugi M, et al: DeltaN133p53 expression levels in relation to haplotypes of the TP53 internal promoter region. Hum Mutat. 31:456–465. 2010. View Article : Google Scholar : PubMed/NCBI
71	Li X, Dumont P, Della Pietra A, Shetler C and Murphy ME: The codon 47 polymorphism in p53 is functionally significant. J Biol Chem. 280:24245–24251. 2005. View Article : Google Scholar : PubMed/NCBI
72	National Institute for Health and Care Excellence (NICE): Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancerClinical guideline [CG164]. NICE; London: 2013, https://www.nice.org.uk/guidance/cg164June. 2013
73	The Institute of Cancer Research (ICR): Division of Genetics and EpidemiologyICR; London: https://www.icr.ac.uk/our-research/research-divisions/division-of-genetics-and-epidemiologyCancer Genetic Clinical Protocols.